Literature DB >> 7479468

Hyperkalaemia in diabetes: prevalence and associations.

P R Jarman1, A M Kehely, H M Mather.   

Abstract

Hyperkalaemia is associated with diabetes, but there are no recent reports of its prevalence and associations. Serum potassium concentrations were measured in all 1764 patients attending a diabetic clinic over a 12-month period and found to be > 5.0 mmol/l in 270 (15%), and > 5.4 mmol/l in 67 (4%). There was no other evident cause of hyperkalaemia in 41 of these 67 patients. These data serve to highlight the risk of dangerous hyperkalaemia in diabetic patients, particularly with concurrent administration of angiotensin-converting-enzyme inhibitors and potassium-sparing diuretics.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479468      PMCID: PMC2398240          DOI: 10.1136/pgmj.71.839.551

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  9 in total

1.  Effect of hyperglycemia on plasma sodium and potassium concentration revisited.

Authors:  R A Shalwitz; R L Gingerich; J B McGill; J M McDonald
Journal:  Clin Chem       Date:  1991-02       Impact factor: 8.327

2.  Nonuremic diabetic hyperkalemia. Possible role of insulin deficiency.

Authors:  R A DeFronzo; R S Sherwin; P Felig; M Bia
Journal:  Arch Intern Med       Date:  1977-07

3.  Hyperkalemia and hyporeninemic hypoaldosteronism.

Authors:  R A DeFronzo
Journal:  Kidney Int       Date:  1980-01       Impact factor: 10.612

4.  Paradoxical glucose-induced hyperkalemia. Combined aldosterone-insulin deficiency.

Authors:  S Goldfarb; B Strunk; I Singer; M Goldberg
Journal:  Am J Med       Date:  1975-11       Impact factor: 4.965

5.  Effect of acute hyperglycaemia on plasma potassium and aldosterone levels in type 2 (non-insulin-dependent) diabetes.

Authors:  J Rosenstock; S A Loizou; I E Brajkovich; K Mashiter; G F Joplin
Journal:  Diabetologia       Date:  1982-03       Impact factor: 10.122

6.  Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.

Authors:  D M Large; P H Carr; I Laing; M Davies
Journal:  Postgrad Med J       Date:  1984-05       Impact factor: 2.401

7.  Aldosterone responsiveness in patients with diabetes mellitus.

Authors:  A R Christlieb; A Kaldany; J A D'Elia; G H Williams
Journal:  Diabetes       Date:  1978-07       Impact factor: 9.461

8.  Hyporeninemic hypoaldosteronism. An overlooked cause of hyperkalemia.

Authors:  S Y Tan; M Burton
Journal:  Arch Intern Med       Date:  1981-01

9.  Reduction of erythrocyte (Na(+)-K+) ATPase activities in non-insulin-dependent diabetic patients with hyperkalemia.

Authors:  M Mimura; H Makino; A Kanatsuka; S Yoshida
Journal:  Metabolism       Date:  1992-04       Impact factor: 8.694

  9 in total
  9 in total

1.  Diabetes may be independent risk factor for hyperkalaemia.

Authors:  Paul R Jarman; Hugh M Mather
Journal:  BMJ       Date:  2003-10-04

2.  Effect of diabetes on serum potassium concentrations in acute coronary syndromes.

Authors:  K Foo; N Sekhri; A Deaner; C Knight; A Suliman; K Ranjadayalan; A D Timmis
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

3.  Hospital-acquired hyperkalaemia.

Authors:  N C Bacon
Journal:  Postgrad Med J       Date:  1997-07       Impact factor: 2.401

4.  How to Improve Adherence to Life-saving Heart Failure Treatments with Potassium Binders.

Authors:  Mitja Lainscak
Journal:  Card Fail Rev       Date:  2017-04

5.  Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia.

Authors:  Yosuke Nakayama; Kaoru Ueda; Sho-Ichi Yamagishi; Miki Sugiyama; Chika Yoshida; Yuka Kurokawa; Nao Nakamura; Tomofumi Moriyama; Goh Kodama; Tomohisa Minezaki; Sakuya Ito; Akiko Nagata; Kensei Taguchi; Junko Yano; Yusuke Kaida; Kazutaka Shibatomi; Kei Fukami
Journal:  Clin Exp Nephrol       Date:  2017-04-18       Impact factor: 2.801

6.  Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.

Authors:  Yshai Yavin; Traci A Mansfield; Agata Ptaszynska; Kristina Johnsson; Shamik Parikh; Eva Johnsson
Journal:  Diabetes Ther       Date:  2016-01-12       Impact factor: 2.945

Review 7.  Hyperkalemia in ambulant postcardiac surgery patients during combined therapy with angiotensin-converting enzyme inhibitor, spironolactone, and diet rich in potassium: A report of two cases and review of literature.

Authors:  Aanchal Dixit; Gauranga Majumdar; Prabhat Tewari
Journal:  Ann Card Anaesth       Date:  2019 Apr-Jun

8.  Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study.

Authors:  Eugenia Espinel; Jorge Joven; Iván Gil; Pilar Suñé; Berta Renedo; Joan Fort; Daniel Serón
Journal:  BMC Res Notes       Date:  2013-08-01

9.  Mineralocorticoid receptor antagonists for heart failure: a real-life observational study.

Authors:  Noemi Bruno; Gianfranco Sinagra; Stefania Paolillo; Alice Bonomi; Ugo Corrà; Massimo Piepoli; Fabrizio Veglia; Elisabetta Salvioni; Rocco Lagioia; Marco Metra; Giuseppe Limongelli; Gaia Cattadori; Angela B Scardovi; Valentina Carubelli; Domenico Scrutino; Roberto Badagliacca; Marco Guazzi; Rosa Raimondo; Piero Gentile; Damiano Magrì; Michele Correale; Gianfranco Parati; Federica Re; Mariantonietta Cicoira; Maria Frigerio; Maurizio Bussotti; Carlo Vignati; Fabrizio Oliva; Alessandro Mezzani; Giuseppe Vergaro; Andrea Di Lenarda; Claudio Passino; Susanna Sciomer; Giuseppe Pacileo; Roberto Ricci; Mauro Contini; Anna Apostolo; Pietro Palermo; Massimo Mapelli; Cosimo Carriere; Francesco Clemenza; Simone Binno; Romualdo Belardinelli; Carlo Lombardi; Pasquale Perrone Filardi; Michele Emdin; Piergiuseppe Agostoni
Journal:  ESC Heart Fail       Date:  2018-02-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.